Used as a potent and selective inhibitor of dipeptidyl peptidase-4 (DPP-4), this compound plays a key role in the management of type 2 diabetes. It enhances the activity of incretin hormones, which stimulate insulin release in a glucose-dependent manner, helping to lower blood glucose levels without causing significant hypoglycemia. Due to its favorable pharmacokinetic profile and oral bioavailability, it is developed for use in once-daily dosing regimens. Its structure allows for strong binding affinity and prolonged duration of action, making it a candidate for improving glycemic control in diabetic patients.